KPRX
NASDAQKiora Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.67+0.63 (+30.64%)
2026-03-042026-06-05
News · 26 weeks21-25%
2025-12-142026-06-07
Mix1890d
- SEC Filings12(67%)
- Insider6(33%)
Latest news
25 items- SECSEC Form 424B3 filed by Kiora Pharmaceuticals Inc.424B3 - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form EFFECT filed by Kiora Pharmaceuticals Inc.EFFECT - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form S-3 filed by Kiora Pharmaceuticals Inc.S-3 - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECKiora Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form 10-Q filed by Kiora Pharmaceuticals Inc.10-Q - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form DEF 14A filed by Kiora Pharmaceuticals Inc.DEF 14A - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form D filed by Kiora Pharmaceuticals Inc.D - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECKiora Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- INSIDERSEC Form 4 filed by Tosca Melissa4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4 filed by Daniels Eric Joseph4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4 filed by Strem Brian M.4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- SECKiora Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form S-8 filed by Kiora Pharmaceuticals Inc.S-8 - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECKiora Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form 10-K filed by Kiora Pharmaceuticals Inc.10-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- INSIDERSEC Form 4 filed by Kiora Pharmaceuticals Inc.4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERSEC Form 4 filed by Kiora Pharmaceuticals Inc.4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERPresident and CEO Strem Brian M. was granted 16,733 shares, increasing direct ownership by 36% to 62,598 units (SEC Form 4)4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERChief Development Officer Daniels Eric Joseph covered exercise/tax liability with 238 shares, decreasing direct ownership by 0.90% to 26,137 units (SEC Form 4)4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- INSIDERPresident and CEO Strem Brian M. covered exercise/tax liability with 238 shares, decreasing direct ownership by 0.52% to 45,865 units (SEC Form 4)4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kiora Pharmaceuticals Inc.SCHEDULE 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)
- SECKiora Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- SECSEC Form 10-Q filed by Kiora Pharmaceuticals Inc.10-Q - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
- PRKiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular DisordersENCINITAS, Calif. and WASHINGTON D.C., Oct. 30, 2025 /PRNewswire/ -- Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) and Global Genes today announced that Kiora has joined Global Genes' RARE-X Vision Consortium, a corporate-nonprofit partnership with a mission to promote and facilitate collaboration among advocacy, research, and industry stakeholders to advance research leading to vision-improving therapies. The Vision Consortium aims to transform the lives of people affected by rare ocular disorders by identifying clinical trial ready populations, ensuring meaningful outcome measures, and accelerating the development of clinical trial programs required to bring new treatments to patients.
- SECSEC Form EFFECT filed by Kiora Pharmaceuticals Inc.EFFECT - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
KPRX FAQ
6 questionsWhat does Kiora Pharmaceuticals Inc. do?
Kiora Pharmaceuticals, Inc., an ophthalmic specialty pharmaceutical company, develops therapies for the treatment of eye diseases in the United States. Its pipeline includes KIO-101, a small molecule DHODH inhibitor that treats immunologic eye diseases; KIO-201, an eye drop that enhances ocular wound healing and protects the ocular surface; and KIO-301, a small molecule that has the potential to restore vision in patients with inherited or age related retinal degeneration. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in...Where does KPRX stock trade?
Kiora Pharmaceuticals Inc. (KPRX) is listed on NASDAQ.What sector and industry is KPRX in?
Kiora Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about KPRX?
Kiora Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $250.00 price target on 2022-01-19. Recent price targets cluster around $250.00.What companies are similar to KPRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare KPRX side-by-side with any of them on Quantisnow.How can I track KPRX on Quantisnow?
Quantisnow aggregates Kiora Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KPRX to receive live email and push alerts on every new disclosure.